📊 Top PSU Shares in India 2024 📊
🔸 NMDC
🔸 Mazagaon Dock Shipbuilders
🔸 Engineers India
🔸 SBI
🔸 Bharat Electronics
🔸 ONGC
🔸 Coal India
🔸 IREDA
🔸 RITES
🔸 RVNL
🔸 Power Finance Corporation
🔸 NMDC
🔸 Mazagaon Dock Shipbuilders
🔸 Engineers India
🔸 SBI
🔸 Bharat Electronics
🔸 ONGC
🔸 Coal India
🔸 IREDA
🔸 RITES
🔸 RVNL
🔸 Power Finance Corporation
👍35❤8
#Learning
What is ASM?
ASM LT Stage 1 refers to a regulatory measure used by stock exchanges to monitor and manage trading activities. Here's a breakdown of the term:
ASM: Additional Surveillance Measure
LT: Long Term
Stage 1: The first level or stage of monitoring
ASM LT Stage 1 specifically refers to the initial stage of long-term additional surveillance measures imposed by the stock exchange.
These measures are put in place to ensure market integrity and to safeguard the interests of investors.
Stocks that are placed under ASM are subject to enhanced scrutiny due to factors like unusual price movements, volatility, or other concerns that may pose risks to investors.
Typical measures under ASM LT Stage 1
When a stock is placed under ASM LT Stage 1, the following measures may be implemented:
Increased Margins: Higher margins may be required for trading the stock.
Trade-to-Trade Settlement: All trades must be settled on a trade-to-trade basis, meaning no intraday trading is allowed.
Price Band Changes: There may be tighter price bands to limit the daily price movement of the stock.
Time frame Securities which have completed 90 trading days in the long-term ASM shall be liable to exit the list. Also, the stage review shall be done weekly
What is ASM?
ASM LT Stage 1 refers to a regulatory measure used by stock exchanges to monitor and manage trading activities. Here's a breakdown of the term:
ASM: Additional Surveillance Measure
LT: Long Term
Stage 1: The first level or stage of monitoring
ASM LT Stage 1 specifically refers to the initial stage of long-term additional surveillance measures imposed by the stock exchange.
These measures are put in place to ensure market integrity and to safeguard the interests of investors.
Stocks that are placed under ASM are subject to enhanced scrutiny due to factors like unusual price movements, volatility, or other concerns that may pose risks to investors.
Typical measures under ASM LT Stage 1
When a stock is placed under ASM LT Stage 1, the following measures may be implemented:
Increased Margins: Higher margins may be required for trading the stock.
Trade-to-Trade Settlement: All trades must be settled on a trade-to-trade basis, meaning no intraday trading is allowed.
Price Band Changes: There may be tighter price bands to limit the daily price movement of the stock.
Time frame Securities which have completed 90 trading days in the long-term ASM shall be liable to exit the list. Also, the stage review shall be done weekly
👍17👌13❤3😱2
🌞Top 6 Solar Pump Stocks in India🌞
🌲 In recent years, the demand for pumps has increased across all market segments.
🌲 The government's focus on irrigation, sanitation, drinking water supply, and urban housing projects are the key factors driving the demand for pumps.
1️⃣ Shakti Pumps
2️⃣ Kirloskar Brothers Ltd
3️⃣ KSB Ltd
4️⃣ WPIL
5️⃣ Latteys Industries
6️⃣ Aqua Pumps
🌲 In recent years, the demand for pumps has increased across all market segments.
🌲 The government's focus on irrigation, sanitation, drinking water supply, and urban housing projects are the key factors driving the demand for pumps.
1️⃣ Shakti Pumps
2️⃣ Kirloskar Brothers Ltd
3️⃣ KSB Ltd
4️⃣ WPIL
5️⃣ Latteys Industries
6️⃣ Aqua Pumps
🔥28👍18
🏥Apollo Hospital Enterprise Ltd
Apollo Hospital Enterprise Ltd is one of the leading integrated healthcare service providers in Asia. It has a presence in hospital, pharmaceutical, primary care & diagnostic clinics. It also has telemedicine units across 10 countries, health insurance services, global projects consultancy, colleges of nursing and hospital management and a research foundation, epidemiological studies, stem cell & genetic research. The healthcare has 73 hospitals, with total bed capacity of 10,103 beds as on 31st December 2023. Of these, 45 hospitals are owned including subsidiaries, JVs, and associates, and 6 are managed hospitals. It also has 22 ambulatory care & birthing centers. Besides its hospital-based pharmacies, AHEL runs pharmacy operations under 'Apollo Pharmacy' through a retail pharmacy chain of 5,790 outlets. Apollo Healthcare and .ifestyle (AHLL) subsidiary covers the retail healthcare business of the Apollo group, comprising Apollo Clinics, Apollo Sugar, White Dental, Apollo Day Surgery centres and Apollo Cradle.
Apollo Hospital Enterprise Ltd is one of the leading integrated healthcare service providers in Asia. It has a presence in hospital, pharmaceutical, primary care & diagnostic clinics. It also has telemedicine units across 10 countries, health insurance services, global projects consultancy, colleges of nursing and hospital management and a research foundation, epidemiological studies, stem cell & genetic research. The healthcare has 73 hospitals, with total bed capacity of 10,103 beds as on 31st December 2023. Of these, 45 hospitals are owned including subsidiaries, JVs, and associates, and 6 are managed hospitals. It also has 22 ambulatory care & birthing centers. Besides its hospital-based pharmacies, AHEL runs pharmacy operations under 'Apollo Pharmacy' through a retail pharmacy chain of 5,790 outlets. Apollo Healthcare and .ifestyle (AHLL) subsidiary covers the retail healthcare business of the Apollo group, comprising Apollo Clinics, Apollo Sugar, White Dental, Apollo Day Surgery centres and Apollo Cradle.
👍14❤1
#SALES #GROWTH
In FY23, revenue was ₹16,612 cr, a growth of 13% YoY. ARPOB for the period was ₹51,668, up by 14% YoY with an increase in patient volumes by 18% YoY. In 9M FY24, revenue was ₹14,116 cr, up by 15% YoY. Revenue growth was seen across all the segments, The blended ARPOB for the period was ₹56,823 up by 10% YoY with an increase in-patient volumes by 5% YoY. ARPOB growth was aided bv an increased
Going forward, better case mix, higher contribution from international patients and optimum occupancy IS likely to drive the topline growth. Over the next few years, it is looking to improve occupancy to 70%- 72%, from the current levels of 65% in 9M FY24. On retail health, its specific focus is on primary care in diagnostics and expect the division to generate revenue of ₹500 cr by FY24 and achieve topline of ₹1,000 cr over the next 3 years.
In FY23, revenue was ₹16,612 cr, a growth of 13% YoY. ARPOB for the period was ₹51,668, up by 14% YoY with an increase in patient volumes by 18% YoY. In 9M FY24, revenue was ₹14,116 cr, up by 15% YoY. Revenue growth was seen across all the segments, The blended ARPOB for the period was ₹56,823 up by 10% YoY with an increase in-patient volumes by 5% YoY. ARPOB growth was aided bv an increased
Going forward, better case mix, higher contribution from international patients and optimum occupancy IS likely to drive the topline growth. Over the next few years, it is looking to improve occupancy to 70%- 72%, from the current levels of 65% in 9M FY24. On retail health, its specific focus is on primary care in diagnostics and expect the division to generate revenue of ₹500 cr by FY24 and achieve topline of ₹1,000 cr over the next 3 years.
5 Year CAGR: 15.0%👍9
#EBITDA #GROWTH
In FY23, EBITDA was ₹2,050 cr, a decline of 6% YoY.In 9M FY24, EBITDA was ₹1,751 cr, a growth of 12% YOY. The company remains focused on expanding and investing aggressively in its digital platform, thereby restricting the operational performance, in the near term.
5 Year CAGR: 20.9%
In FY23, EBITDA was ₹2,050 cr, a decline of 6% YoY.In 9M FY24, EBITDA was ₹1,751 cr, a growth of 12% YOY. The company remains focused on expanding and investing aggressively in its digital platform, thereby restricting the operational performance, in the near term.
5 Year CAGR: 20.9%
🔥8👍2
#PAT #GROWTH
In FY23, PAT was ₹888 cr, a decline of 19% YoY. This was due to exceptional gain of ₹294 cr in Q1 FY22. PAT growth was also impacted by lower operating profit.In 9M FY24, PAT was ₹668 cr, a decline of10% YoY. Profit during the period was impacted mainly due to higher finance and tax costs. the pick up in primary and secondary patient care, elective surgeries, addition of laboratories & collection centers in the diagnostic business coupled with focus on private label sales is likely to drive earnings growth.
In FY23, PAT was ₹888 cr, a decline of 19% YoY. This was due to exceptional gain of ₹294 cr in Q1 FY22. PAT growth was also impacted by lower operating profit.In 9M FY24, PAT was ₹668 cr, a decline of10% YoY. Profit during the period was impacted mainly due to higher finance and tax costs. the pick up in primary and secondary patient care, elective surgeries, addition of laboratories & collection centers in the diagnostic business coupled with focus on private label sales is likely to drive earnings growth.
👍7
#EBITDA #MARGIN
In FY23, EBITDA margin was 12.34%, a contraction of a 256 bps YoY. In 9M FY24, EBITDA margin was 12.4%, a contraction of 28 bps YoY. The margin was impacted due to the reduced share of elective and surgical revenue in the revenue mix due to the holiday and festive season, as well as investments in clinical talent, which is yet to be fully optimized.further increasing occupancy rate, payor mix, case mix and cost optimisation efforts are likely to aid in margin growth. However, this may be partially offset by the increased investment in Apollo 24/7 coupled with non cash expense arising out of ESOP charge which will continue for the next three years.
In FY23, EBITDA margin was 12.34%, a contraction of a 256 bps YoY. In 9M FY24, EBITDA margin was 12.4%, a contraction of 28 bps YoY. The margin was impacted due to the reduced share of elective and surgical revenue in the revenue mix due to the holiday and festive season, as well as investments in clinical talent, which is yet to be fully optimized.further increasing occupancy rate, payor mix, case mix and cost optimisation efforts are likely to aid in margin growth. However, this may be partially offset by the increased investment in Apollo 24/7 coupled with non cash expense arising out of ESOP charge which will continue for the next three years.
👍6
#ROCE
In FY23, ROCE was 17.78%. The moderation in operating profitability had a bearing on the metric.
In FY23, ROCE was 17.78%. The moderation in operating profitability had a bearing on the metric.
⚡5👍5😱1
#ROE
Apolo Hospitals Enterprise Ltd. ROE was 15.16%. This moderation can be attributed to a higher base from the previous year, which was supported by exceptional gain of ₹294 cr
Apolo Hospitals Enterprise Ltd. ROE was 15.16%. This moderation can be attributed to a higher base from the previous year, which was supported by exceptional gain of ₹294 cr
👍9
#Management #Outlook
Apollo Health Co will leverage Keimed's vast network of more than 70,000 stores to accelerate its ₹1,500 cr private label portfolio. The combined entity is likely to generate revenue of ₹25,000 cr in 3 years with 7%-8% of EBITDA margin.
Apollo Health Co will leverage Keimed's vast network of more than 70,000 stores to accelerate its ₹1,500 cr private label portfolio. The combined entity is likely to generate revenue of ₹25,000 cr in 3 years with 7%-8% of EBITDA margin.
👍13
Companies Manufacture Drones in India
I) Government-Owned Giants
1️⃣ HAL
II) Military Drone Leaders
1️⃣ L&T
2️⃣ Zen Technologies
3️⃣ DCM Shriram
III) Commercial Drone Service Providers
1️⃣ Info Edge
2️⃣ Drone Destination
3️⃣ Droneacharya
4️⃣ Rattanindia Enterprises
IV) Drone Technologies
1️⃣ Paras Defence
2️⃣ Bharat Forge
I) Government-Owned Giants
1️⃣ HAL
II) Military Drone Leaders
1️⃣ L&T
2️⃣ Zen Technologies
3️⃣ DCM Shriram
III) Commercial Drone Service Providers
1️⃣ Info Edge
2️⃣ Drone Destination
3️⃣ Droneacharya
4️⃣ Rattanindia Enterprises
IV) Drone Technologies
1️⃣ Paras Defence
2️⃣ Bharat Forge
👍29❤5